Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0LUZKB)
| ADC Name |
FS001
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
FS001; ESG408; IPN60300
Click to Show/Hide
|
|||||
| Organization |
Shanghai Escugen Biotechnology (Escugen) (Originator);Foreseen Biotechnology (Originator);Ipsen
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Antibody Name |
Undisclosed
|
Antigen Name |
Undisclosed
|
|||
| Payload Name |
TOP1 inhibitor
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|